GLP-1受体激动剂与2型糖尿病患者自杀风险研究
这项在英國基层医疗数据库开展的活性对照、新用药者队列研究显示,2型糖尿病患者使用GLP-1受体激动剂与使用DPP-4抑制剂或SGLT-2抑制剂相比,在校正混杂因素后自杀意念、自伤和自杀的复合风险无显著升高。粗分析中观察到的风险升高在倾向评分加权后消失。
要点
- 校正混杂后,GLP-1受体激动剂与DPP-4抑制剂相比自杀风险无显著差异(HR 1.02)。
- 与SGLT-2抑制剂相比,校正后同样未见自杀风险升高(HR 0.91)。
- 粗分析中的风险升高可能由混杂因素解释,临床决策应关注患者整体情况。
核心结论
- 在2型糖尿病患者中,使用GLP-1受体激动剂与使用DPP-4抑制剂或SGLT-2抑制剂相比,未观察到自杀意念、自伤和自杀复合结局风险升高。
研究设计与样本
- 活性对照、新用药者队列研究,数据来自英国临床实践研究数据链(CPRD),链接住院统计和死亡登记数据库。
- 第一队列为2007年1月1日至2020年12月31日期间开始并持续使用GLP-1受体激动剂或DPP-4抑制剂的患者,随访至2021年3月29日。
- 第二队列为2013年1月1日至2020年12月31日期间开始并持续使用GLP-1受体激动剂或SGLT-2抑制剂的患者,随访至2021年3月29日。
- 采用倾向评分精细分层加权Cox比例风险模型估计风险比和95%CI。
主要发现
- 第一队列纳入36 082例GLP-1受体激动剂使用者(中位随访1.3年)和234 028例DPP-4抑制剂使用者(中位随访1.7年)。
- 粗分析中GLP-1受体激动剂组自杀复合结局粗发生率3.9/1000人年,DPP-4抑制剂组1.8/1000人年,HR 2.08(95%CI 1.83至2.36)。
- 校正混杂后HR降至1.02(95%CI 0.85至1.23)。
- 第二队列纳入32 336例GLP-1受体激动剂使用者(中位随访1.2年)和96 212例SGLT-2抑制剂使用者(中位随访1.2年)。
- 粗分析中GLP-1受体激动剂组粗发生率4.3/1000人年,SGLT-2抑制剂组2.7/1000人年,HR 1.60(95%CI 1.37至1.87),校正后HR 0.91(95%CI 0.73至1.12)。
关键数值与推荐
- 主要结局为自杀相关复合结局,定义为自杀意念、自伤和自杀的复合终点;次要结局为各事件单独分析。
- 两个队列中自杀意念、自伤和自杀单独分析结果与复合结局一致。
临床怎么用
- 对于2型糖尿病患者,现有证据不支持GLP-1受体激动剂增加自杀风险,临床处方时无需因该担忧而回避。
- 既往有精神心理疾病或自杀风险的患者仍应常规评估和随访,不应仅依据本研究的总体结果而放松警惕。
局限性
- 观察性设计,尽管采用倾向评分加权校正混杂,仍可能存在未测量混杂。
- 中位随访时间较短(1.2至1.7年),长期风险无法评估。
- 数据来自英国基层医疗数据库,结果外推至其他人群时需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors. DESIGN: Active comparator, new user cohort study. SETTING: Primary care practices contributing data to the UK Clinical Practice Research Datalink linked to the Hospital Episodes Statistics Admitted Patient Care and Office for National Statistics Death Registration databases. PARTICIPANTS: Patients with type 2 diabetes. EXPOSURES: Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020. Both cohorts were followed until 29 March 2021. MAIN OUTCOME MEASURES: The primary outcome was suicidality, defined as a composite of suicidal ideation, self-harm, and suicide. Secondary outcomes were each of these events considered separately. Propensity score fine stratification weighted Cox proportional hazards models were fitted to estimate hazard ratios and 95% confidence intervals (CIs) to estimate the average treatment effect among the treated patients. RESULTS: The first cohort included 36 082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234 028 DPP-4 inhibitor users (median follow-up 1.7 years). In crude analyses, GLP-1 receptor agonist use was associated with an increased incidence of suicidality compared with DPP-4 inhibitors (crude incidence rates 3.9 v 1.8 per 1000 person years, respectively; hazard ratio 2.08, 95% CI 1.83 to 2.36). This estimate decreased to a null value after confounding factors were accounted for (hazard ratio 1.02, 95% CI 0.85 to 1.23). The second cohort included 32 336 GLP-1 receptor agonist users (median follow-up 1.2 years) and 96 212 SGLT-2 inhibitor users (median follow-up 1.2 years). Similarly, GLP-1 receptor agonist use was associated with an increased risk of suicidality compared with SGLT-2 inhibitors in crude analyses (crude incidence rates 4.3 v 2.7 per 1000 person years; hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12). Similar findings were observed when suicidal ideation, self-harm, and suicide were analysed separately in both cohorts. CONCLUSIONS: In this large cohort study, the use of GLP-1 receptor agonists was not associated with an increased risk of suicidality compared with the use of DPP-4 inhibitors or SGLT-2 inhibitors in patients with type 2 diabetes.
引用
- Shapiro SB, Yin H, Yu OHY, et al. Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. BMJ. 2025. PMID: 40010803. doi:10.1136/bmj-2024-080679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。